FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989044972> ?p ?o ?g. }

• W2989044972 endingPage "2744" @default.
• W2989044972 startingPage "2744" @default.
• W2989044972 abstract "Little is known about the disease-specific factors that predict responsiveness to CAR-T cell therapy, other the direct presence of the CAR-T target. Clinical outcomes at our center have demonstrated that durable responses to CD19-directed CAR-T therapy in pediatric pre-B-ALL (acute lymphoblastic leukemia) are associated with persistence of CAR-T cells in the peripheral blood, antigenic load (percent CD19-positive cells in marrow prior to CAR-T infusion), and apheresis product T-cell quality (Finney O, et al., 2019). However, in a small number of cases where both antigenic load and T-cell quality predicted a good response, the treatment failed rapidly. This led us to undertake a detailed investigation of the leukemia itself in order to discover potential disease-associated factors that correlate with resistance to CAR-T therapy. We employed advanced exomic, and single-cell genomic and epigenomic analysis techniques to define signatures present in four CD19-CAR-T resistant bone marrow biopsy specimens, in comparison to five specimens from CD19-CAR-T responsive disease, from patients enrolled in a phase I clinical trial at Seattle Children's Hospital (PLAT-02, NCT02028455). Current cytogenic approaches to identify high risks markers (Ph+, Ph-like, MLL) were not informative as to CAR-T susceptibility, as high risk leukemias were CAR-T responsive; while a CAR-T resistant leukemia contained a marker (ETV6-RUNX1 fusion) previously associated with a good prognosis. Thus, we performed bulk whole-exome sequencing and RNAseq, single cell (sc) RNAseq, sc B-cell receptor (BCR)-seq, methylation array, H3K27ac ChIPseq, and ATACseq on these marrow samples. Initial genomic analysis revealed a total of 5 previously described hotspot mutations in ABL1, IKZF1, EP300, and 2 in KRAS. RNAseq analyses identified actionable fusions for ABL1, ETV6, ETV5, and KMT2A. Interestingly, a therapy-sensitive leukemia harbored a KMT2A-AFF1 fusion that was shown to predispose patients to leukemic plasticity and lineage switching when treated with blinatumomab. Importantly, we identified CREBBP-fusions in leukemias that failed to achieve CD19-CAR-T cell induced B cell aplasia. CREBBP perturbations have previously been associated with relapsed and refractory ALL, but not with resistance to CAR-T therapy. Single cell RNAseq and scBCRseq data are being analyzed for the existence of mixed lineage and gene expression-based heterogeneity that may predict clonal selection under CAR-T pressure. RNASeq analysis identified upregulation of JUN and JUND transcripts in CAR-T resistant disease, a finding which is complemented by the hypermethylation of JUND in CAR-T sensitive disease. Similarly, ATACseq and methylation data is being analyzed for lineage specification in CAR-T resistant leukemia. In comparing dysfunctional to functional CAR-T responders by ATACseq, > 10,000 unique open chromatin regions were identified in dysfunctional responders, as opposed to <500 open chromatin regions in the functional responders, indicating that CAR-T resistant disease had more open chromatin. A recent published analysis of cancer cell lines identified EP300 and CREBBP mutations that were proposed to increase substrate acetylation, and which …may represent the first cancer-associated gain of function mutations for p300 and CBP… (Ghandi M, et al, 2019). Our study represents one of the most comprehensive approaches to genomic profiling for B-ALL patient samples to date. The immune evasion we have described is not due to overt CD19 antigen loss, or to a long-term process of genetic alteration or drift. We propose that continued analysis of our data may reveal that epigenetic plasticity is a component of CAR-T resistance. The presence of CREBBP fusion genes or mutations, methylation array-based identification of altered JUND/JUN regulation, and ATAC Seq identification of multiple open regions of the genome in leukemias from dysfunctional responders lend support to this hypothesis. Although our analysis is preliminary and the sample number is small, we believe these in-depth analyses will highlight crucial differences in leukemia that predict responsiveness to CAR T therapy Disclosures Gardner: Novartis: Honoraria. Jensen:Bluebird Bio: Research Funding; Juno Therapeutics, a Celgene Company: Research Funding. Orentas:Lentigen Technology Inc., a Miltenyi Biotec Company: Consultancy, Research Funding." @default.
• W2989044972 created "2019-11-22" @default.
• W2989044972 creator A5006124524 @default.
• W2989044972 creator A5007178705 @default.
• W2989044972 creator A5010964073 @default.
• W2989044972 creator A5013596800 @default.
• W2989044972 creator A5017546318 @default.
• W2989044972 creator A5017823342 @default.
• W2989044972 creator A5023585989 @default.
• W2989044972 creator A5040487857 @default.
• W2989044972 creator A5045973874 @default.
• W2989044972 creator A5047748413 @default.
• W2989044972 creator A5048930616 @default.
• W2989044972 creator A5073151063 @default.
• W2989044972 creator A5075293839 @default.
• W2989044972 creator A5077990667 @default.
• W2989044972 creator A5081312498 @default.
• W2989044972 creator A5081457672 @default.
• W2989044972 creator A5082052104 @default.
• W2989044972 creator A5088464124 @default.
• W2989044972 date "2019-11-13" @default.
• W2989044972 modified "2023-09-28" @default.
• W2989044972 title "Detailed Multi-Method Analysis of Bone Marrow from Pediatric Pre-B-ALL Patients Prior to CD19-CAR-T Therapy Subsequently Evidencing Overt CAR-T Resistance" @default.
• W2989044972 doi "https://doi.org/10.1182/blood-2019-130796" @default.
• W2989044972 hasPublicationYear "2019" @default.
• W2989044972 type Work @default.
• W2989044972 sameAs 2989044972 @default.
• W2989044972 citedByCount "3" @default.
• W2989044972 countsByYear W29890449722020 @default.
• W2989044972 countsByYear W29890449722022 @default.
• W2989044972 crossrefType "journal-article" @default.
• W2989044972 hasAuthorship W2989044972A5006124524 @default.
• W2989044972 hasAuthorship W2989044972A5007178705 @default.
• W2989044972 hasAuthorship W2989044972A5010964073 @default.
• W2989044972 hasAuthorship W2989044972A5013596800 @default.
• W2989044972 hasAuthorship W2989044972A5017546318 @default.
• W2989044972 hasAuthorship W2989044972A5017823342 @default.
• W2989044972 hasAuthorship W2989044972A5023585989 @default.
• W2989044972 hasAuthorship W2989044972A5040487857 @default.
• W2989044972 hasAuthorship W2989044972A5045973874 @default.
• W2989044972 hasAuthorship W2989044972A5047748413 @default.
• W2989044972 hasAuthorship W2989044972A5048930616 @default.
• W2989044972 hasAuthorship W2989044972A5073151063 @default.
• W2989044972 hasAuthorship W2989044972A5075293839 @default.
• W2989044972 hasAuthorship W2989044972A5077990667 @default.
• W2989044972 hasAuthorship W2989044972A5081312498 @default.
• W2989044972 hasAuthorship W2989044972A5081457672 @default.
• W2989044972 hasAuthorship W2989044972A5082052104 @default.
• W2989044972 hasAuthorship W2989044972A5088464124 @default.
• W2989044972 hasBestOaLocation W29890449721 @default.
• W2989044972 hasConcept C126322002 @default.
• W2989044972 hasConcept C143998085 @default.
• W2989044972 hasConcept C147483822 @default.
• W2989044972 hasConcept C203014093 @default.
• W2989044972 hasConcept C2776090121 @default.
• W2989044972 hasConcept C2778461978 @default.
• W2989044972 hasConcept C2778957590 @default.
• W2989044972 hasConcept C2780007613 @default.
• W2989044972 hasConcept C3875195 @default.
• W2989044972 hasConcept C502942594 @default.
• W2989044972 hasConcept C71924100 @default.
• W2989044972 hasConcept C8891405 @default.
• W2989044972 hasConceptScore W2989044972C126322002 @default.
• W2989044972 hasConceptScore W2989044972C143998085 @default.
• W2989044972 hasConceptScore W2989044972C147483822 @default.
• W2989044972 hasConceptScore W2989044972C203014093 @default.
• W2989044972 hasConceptScore W2989044972C2776090121 @default.
• W2989044972 hasConceptScore W2989044972C2778461978 @default.
• W2989044972 hasConceptScore W2989044972C2778957590 @default.
• W2989044972 hasConceptScore W2989044972C2780007613 @default.
• W2989044972 hasConceptScore W2989044972C3875195 @default.
• W2989044972 hasConceptScore W2989044972C502942594 @default.
• W2989044972 hasConceptScore W2989044972C71924100 @default.
• W2989044972 hasConceptScore W2989044972C8891405 @default.
• W2989044972 hasIssue "Supplement_1" @default.
• W2989044972 hasLocation W29890449721 @default.
• W2989044972 hasOpenAccess W2989044972 @default.
• W2989044972 hasPrimaryLocation W29890449721 @default.
• W2989044972 hasRelatedWork W2064357373 @default.
• W2989044972 hasRelatedWork W2412656109 @default.
• W2989044972 hasRelatedWork W2912741252 @default.
• W2989044972 hasRelatedWork W2999917694 @default.
• W2989044972 hasRelatedWork W3012325124 @default.
• W2989044972 hasRelatedWork W3136689359 @default.
• W2989044972 hasRelatedWork W3158561770 @default.
• W2989044972 hasRelatedWork W4210550777 @default.
• W2989044972 hasRelatedWork W4213079769 @default.
• W2989044972 hasRelatedWork W4281289906 @default.
• W2989044972 hasVolume "134" @default.
• W2989044972 isParatext "false" @default.
• W2989044972 isRetracted "false" @default.
• W2989044972 magId "2989044972" @default.
• W2989044972 workType "article" @default.